Doç. Dr. NAİL PAKSOY

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Kahraman S., Karakaya S., Kaplan M. A., Goksu S. S., Ozturk A., Isleyen Z. S., et al.

Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded)

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

Taşçı E. Ş., Oyan B., Sönmez Ö., Mutlu A. U., Atcı M. M., Sakin A., et al.

BMC Cancer , cilt.24, sa.1, 2024 (SCI-Expanded)

Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy

Meagher M. F., Minervini A., Mir M. C., Cerrato C., Rebez G., Autorino R., et al.

European Urology Open Science , cilt.63, ss.71-80, 2024 (SCI-Expanded)

Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin and docetaxel (mDCF and mDCX) as a first-line chemotherapy regimen in her 2-negative metastatic gastric cancer patients: A retrospective study

DEMİRCİ N. S., AZİZY A., Paksoy N., Doǧan I., KARABULUT S., Karahan L., et al.

Medicine (United States) , cilt.103, sa.9, 2024 (SCI-Expanded)

Therapeutic efficacy of high-dose chemotherapy with autologous stem-cell transplantation in 44 relapsed or refractory germ-cell tumor patients: A retrospective cohort study

Ferhatoglu F., Paksoy N., Khanmammadov N., YILDIZ A., AHMED M. A., Gülbas Z., et al.

Medicine (United States) , cilt.103, sa.8, 2024 (SCI-Expanded)

Single-agent temozolomide as salvage therapy in heavily pretreated metastatic sarcoma patients

Dogan I., Paksoy N., BAŞARAN M.

Journal of Cancer Research and Therapeutics , cilt.20, sa.1, ss.93-97, 2024 (SCI-Expanded)

The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients

Ak N., Tuz Z., Aydin E., Ferhatoğlu F., Sari M., Paksoy N., et al.

Turkish Journal of Medical Sciences , cilt.54, sa.1, ss.229-238, 2024 (SCI-Expanded)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression

Dogan I., Aydin E., Khanmammadov N., Paksoy N., Saip P., AYDINER A.

Scientific Reports , cilt.13, sa.1, 2023 (SCI-Expanded)

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Karacin C., Oksuzoglu B., Demirci A., KESKİNKILIÇ M., Baytemür N. K., Yılmaz F., et al.

BMC Cancer , cilt.23, sa.1, 2023 (SCI-Expanded)

Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients

Dogan I., Aydin E., Khanmammadov N., Paksoy N., Ferhatoğlu F., Ak N., et al.

Journal of Cancer Research and Clinical Oncology , cilt.149, sa.16, ss.14833-14841, 2023 (SCI-Expanded)

Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience

Pehlivan M., Paksoy N., Aydin E., BAŞARAN M., EKENEL M.

Medicine (United States) , cilt.102, sa.41, 2023 (SCI-Expanded)

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

Ünal Ç., Azizy A., Karabulut S., Taştekin D., Akyıldız A., Yaşar S., et al.

Oncologist , cilt.28, sa.10, ss.875-884, 2023 (SCI-Expanded)

Efficacy and outcomes of systemic chemotherapy in posttransplant and immunosuppression associated Kaposi sarcoma: Twenty years experience of a tertiary cancer center

Khanmammadov N., Paksoy N., Dogan I., Ferhatoglu F., Saip P., AYDINER A.

Medicine (United States) , cilt.102, sa.39, 2023 (SCI-Expanded)

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Hizal M., Bilgin B., Paksoy N., Atcı M. M., Kahraman S., Kılıçkap S., et al.

Journal of Cancer Research and Clinical Oncology , cilt.149, sa.8, ss.4141-4148, 2023 (SCI-Expanded)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

Dogan I., Iribas A., Paksoy N., Vatansever S., BAŞARAN M.

Journal of Cancer Research and Therapeutics , cilt.19, sa.2 S, 2023 (SCI-Expanded)

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Kahraman S., Erul E., Seyyar M., Gumusay O., Bayram E., Demirel B. C., et al.

Future Oncology , cilt.19, sa.10, ss.727-736, 2023 (SCI-Expanded)

Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience

TAŞTEKİN D., Paksoy N., Dogan I., Ferhatoglu F., Khanmammadov N., Bozbey H. U., et al.

Journal of Cancer Research and Therapeutics , cilt.19, sa.2, ss.253-258, 2023 (SCI-Expanded)

Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group

Gürbüz M., Kiliçkap S., BİLİCİ A., Karadurmuş N., Sezer A., ŞENDUR M. A. N., et al.

Medicine (United States) , cilt.101, sa.50, 2022 (SCI-Expanded)

High-dose chemotherapy followed by autologous stem cell transplantation for adult patients with first relapse of Ewing's sarcoma: A single institution experience

Paksoy N., Ferhatoglu F., Dogan İ., Khanmammadov N., Iribas Celik A., Gulbas Z., et al.

Medicine (United States) , cilt.101, sa.49, 2022 (SCI-Expanded)

Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

Gürbüz M., KUTLU Y., Akkuş E., KÖKSOY E. B., Köse N., Öven B. B., et al.

Journal of Cancer Research and Clinical Oncology , cilt.148, sa.12, ss.3547-3555, 2022 (SCI-Expanded)

Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study

Paksoy N., Khanmammadov N., Doǧan İ., Ferhatoǧlu F., YILDIZ A., Ak N., et al.

Medicine (United States) , cilt.101, sa.45, 2022 (SCI-Expanded)

Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC

Dogan I., Gurbuz M., Paksoy N., Ferhatoglu F., Vatansever S., Saip P., et al.

Medicine (United States) , cilt.101, sa.34, 2022 (SCI-Expanded)

Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer

Dogan I., KARABULUT S., TAŞTEKİN D., Ferhatoglu F., Paksoy N., ŞAKAR B.

Journal of the College of Physicians and Surgeons Pakistan , cilt.32, sa.8, ss.1014-1019, 2022 (SCI-Expanded)

Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

Hizal M., Bilgin B., Paksoy N., Klllçkap S., Atcl M. M., Kahraman S., et al.

Future Oncology , cilt.18, sa.23, ss.2573-2582, 2022 (SCI-Expanded)

The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Hizal M., Bilgin B., Paksoy N., AÇIKGÖZ Ö., Sezer A., Gürbüz M., et al.

Journal of Cancer Research and Clinical Oncology , cilt.148, sa.6, ss.1501-1508, 2022 (SCI-Expanded)

Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study

Cil I., Kucukarda A., Atcı M. M., Secmeler S., Paksoy N., Ferhatoglu F., et al.

Tumori , cilt.108, sa.1, ss.19-25, 2022 (SCI-Expanded)

Multidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report

Paksoy N., ERDEM S., Karaca M., Ak N., Pehlivan M., KIZILDAĞ YIRGIN İ., et al.

Journal of Oncology Pharmacy Practice , cilt.28, sa.1, ss.215-221, 2022 (SCI-Expanded)

FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer

Ay S., Atcı M. M., Arıkan R., Dülgar Ö., Özyükseler D. T., Paksoy N., et al.

Journal of Chemotherapy , cilt.34, sa.7, ss.465-471, 2022 (SCI-Expanded)

Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)

Erol C., Sakin A., Başoglu T., Özden E., Çabuk D., Doğan M., et al.

Turkish Journal of Medical Sciences , cilt.52, sa.4, ss.1022-1032, 2022 (SCI-Expanded)

Clinicopathological and Prognostic Features of 67 Cases with Pulmonary Sarcomatoid Carcinoma: An 18-Year Single-Centre Experience

Ferhatoglu F., Amirov F., Ozkan B., Kara M., Toker A., Ak N., et al.

Oncology Research and Treatment , cilt.44, sa.11, ss.590-601, 2021 (SCI-Expanded)

Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences

Tural D., ÖLMEZ Ö. F., Sümbül A. T., Artaç M., Özhan N., Akar E., et al.

European Urology Focus , cilt.7, sa.5, ss.1061-1066, 2021 (SCI-Expanded)

Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

Tural D., ÖLMEZ Ö. F., Sümbül A. T., Özhan N., Çakar B., Köstek O., et al.

International Journal of Clinical Oncology , cilt.26, sa.8, ss.1506-1513, 2021 (SCI-Expanded)

Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?

Has Simsek D., Kuyumcu S., Karadogan S., Oflas M., Isik E. G., Ozkan Z. G., et al.

Annals of Nuclear Medicine , cilt.35, sa.6, ss.680-690, 2021 (SCI-Expanded)

A practical 16-day desensitization protocol in lenalidomide-induced non-immediate hypersensitivity reactions

Demir S., Gelincik A., Coskun R., Ozkan G., Demir N., Paksoy N., et al.

Annals of Allergy, Asthma and Immunology , cilt.123, sa.4, ss.394-397, 2019 (SCI-Expanded)

Analysis of the factors associated with diagnostic skin test positivity in immediate-type hypersensitivity reactions due to proton pump inhibitors

Kepil Özdemir S., Gelincik A., Paksoy N., Köycü Buhari G., Öner Erkekol F., DURSUN A. B., et al.

Allergy: European Journal of Allergy and Clinical Immunology , cilt.74, sa.6, ss.1187-1190, 2019 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler

Predictors of the acquisition of T790M mutation in EGFR mutant metastatic lung cancer patients who were treated with EGFR inhibitors

DOĞAN İ., KHANMAMMADOV N., PAKSOY N., VATANSEVER S., SAİP P. M., AYDINER A.

EURASIAN JOURNAL OF PULMONOLOGY , cilt.25, ss.27-32, 2023 (Hakemli Dergi)

Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine

Doğan İ., Paksoy N., Ak N., Vatansever S., Saip P., AYDINER A.

European Journal of Breast Health , cilt.19, sa.2, ss.128-133, 2023 (ESCI)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience

PAKSOY N., TRABULUS S., SEYAHİ N., ALTIPARMAK M. R.

Namık Kemal Tıp Dergisi , cilt.11, sa.1, ss.27-34, 2023 (Hakemli Dergi)

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study

FERHATOĞLU F., ÇAĞATAY T., OKUMUŞ N. G., AYDINER A., PAKSOY N., AK N., et al.

Eurasian Journal of Medical Investigation , cilt.7, sa.2, ss.101-106, 2023 (Hakemli Dergi)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospita

FERHATOĞLU F., KAPAĞAN T., PAKSOY N., AK N., MEDETALİBEYOĞLU A., ŞENKAL N., et al.

TURK ONKOLOJI DERGISI , cilt.38, sa.1, ss.82-91, 2023 (ESCI)

Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study

Paksoy N., Khanmammadov N., Doǧan İ., Ferhatoǧlu F., AHMED M. A., Karaman S., et al.

Medicine (Spain) , cilt.102, sa.5, 2023 (Scopus)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Unal C., Selcuk N. A., Biricik F. S., Alan O., Ordu C., Selvi O., et al.

Eurasian Journal of Medicine and Oncology , cilt.7, sa.3, ss.232-242, 2023 (ESCI)

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib

DOĞAN İ., KHANMAMMADOV N., PAKSOY N., FERHATOĞLU F., AYDIN E., VATANSEVER S., et al.

TURK ONKOLOJI DERGISI , cilt.37, sa.4, ss.413-418, 2022 (ESCI)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center

FERHATOĞLU F., PAKSOY N., BAŞARAN M.

Namık Kemal Tıp Dergisi , cilt.10, sa.4, ss.350-356, 2022 (Hakemli Dergi)

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study

PAKSOY N., FERHATOĞLU F., DOĞAN İ., KHANMAMMADOV N., BOZBEY H. U., KARABULUT S., et al.

TURK ONKOLOJI DERGISI , cilt.37, sa.4, ss.478-483, 2022 (ESCI)

Evaluation of clinical features and risk factors related to late recurrence (>5 years) in patients with breast cancer

FERHATOĞLU F., AYDINER A., PAKSOY N.

Journal of Surgery and Medicine , cilt.6, sa.12, ss.986-990, 2022 (Hakemli Dergi)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors

PAKSOY N., FERHATOĞLU F., DOĞAN İ., AK N., PEHLİVAN M., EKENEL M., et al.

Eurasian Journal of Medical Investigation , cilt.6, sa.3, ss.326-331, 2022 (Hakemli Dergi)

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib

FERHATOĞLU F., KARABULUT S., PAKSOY N., TAŞTEKİN D.

Eurasian Journal of Medical Investigation , cilt.6, sa.3, ss.292-298, 2022 (Hakemli Dergi)

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma

AK N., PAKSOY N., FERHATOĞLU F., AYDIN E., DOĞAN İ., BEKTAŞ E., et al.

TURK ONKOLOJI DERGISI , cilt.36, sa.4, ss.438-445, 2021 (ESCI)

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer

AK N., PAKSOY N., VELİDEDEOĞLU M., TURNA Z. H., DEMİRELLİ F. H.

Journal of oncological sciences , cilt.7, sa.2, ss.42-49, 2021 (Scopus)

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

Metastasectomy in oligometastatic RCC brings a survival benefit in immunotherapy era: Results from the REMARCC-IO Registry

Primiceri G., Marchioni M., Campi R., Tafuri A., Autorino R., Minervini A., et al.

cilt.83

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

Tasçi E., Oyan B., Sonmez O., Mutlu A., Atci M., Oner I., et al.

cilt.40

Cytoreductive nephrectomy in patients receiving TKI therapy versus immune checkpoint inhibitor therapy: Comparative outcome analysis of the REMARCC registry

Meagher M., Minervini A., Mir M., Rebez G., Autorino R., Campi R., et al.

cilt.79

Predictors of complications after cytoreductive nephrectomy in the immunotherapy era: Results from a multicenter international study

Marchioni M., Rebez G., Campi R., Minervini A., Kriegmair M., Linares E., et al.

cilt.79

Is presence of vena caval thrombosis in primary tumor associated with worsened outcomes in metastatic renal cell carcinoma: Analysis of the REMARCC registry

Meagher M., Mir M., Rebez G., Autorino R., Campi R., Minervini A., et al.

cilt.79

Kitap & Kitap Bölümleri

Yayın

63

Atıf (WoS)

81

H-İndeks (WoS)

5

Atıf (Scopus)

81

H-İndeks (Scopus)

5

Açık Erişim

11

BM Sürdürülebilir Kalkınma Amaçları